Latest News about NVS
Recent news which mentions NVS
From MarketWatch
Novartis Takes Down $80M NASH Pact With Pliant Therapeutics
February 24, 2023
From Benzinga
Better Buy: Beam Therapeutics or Intellia Therapeutics?
February 22, 2023
From Motley Fool
This chart gives one reason European stocks may continue to outperform U.S. equities
February 17, 2023
From MarketWatch
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
February 14, 2023
From Benzinga
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
February 02, 2023
From Benzinga
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors
February 01, 2023
From Benzinga
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
February 01, 2023
Tickers
NVS
From Benzinga
Earnings Scheduled For February 1, 2023
February 01, 2023
From Benzinga
Novartis posts lower sales and profit on generic competition, but boosts 2022 dividend
February 01, 2023
Tickers
NVS
From MarketWatch
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
From InvestorPlace
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump
January 30, 2023
From Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
From Benzinga
Could This Be Novartis' Next Blockbuster Medicine?
January 27, 2023
From Motley Fool
From Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
From InvestorPlace
From Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
January 19, 2023
From Benzinga
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
January 10, 2023
Tickers
NVS
From Benzinga
3 Biotech Companies to Watch in 2023
January 06, 2023
From InvestorPlace
2 Top Biotech Stocks to Buy Right Now
January 06, 2023
From Motley Fool
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
From Benzinga
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
From Motley Fool
From Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.